Condition

Malignant Solid Tumors clinical trials and research

• 13Clinical trials
• 3Countries

Newest Malignant Solid Tumors clinical trials

All recruiting trials (13)

• CAIX-targeted PET/CT imaging in solid tumors

  Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.

  Recruiting Zhongnan Hospital · Wuhan, Hubei · NCT07833085

• TAK-505 treatment for adults with advanced solid tumors

  This trial will test TAK-505, an experimental drug, in adults with locally advanced or metastatic solid tumors (such as stomach, colorectal, non-small cell lung, and head and neck cancers) who have limited standard treatment options.

  Recruiting at 13 sites Phase 1/2 Takeda · Orange, California and 14 other locations · NCT07436728

• SHR-7787 combined with other anti-cancer drugs for malignant solid tumors

  This study will test whether giving SHR-7787 together with other anti-cancer medicines is safe and helps people with unresectable malignant solid tumors.

  Recruiting at 2 sites Phase 2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Wuhan, Hubei and 1 other locations · NCT07268040

• SHR-4298 Injection for Malignant Solid Tumors: a Phase I/II study

  This study tests SHR-4298 injections in adults with advanced solid tumors to see if it is safe, tolerable, and has signs of activity.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Guangzhou, Guangdong · NCT07229612

• SHR-4849 combined with other cancer drugs for malignant solid tumors

  This study will test whether adding SHR-4849 to other cancer drugs is safe and can help adults with malignant solid tumors.

  Recruiting Phase 2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Jinan, Shandong · NCT07028281

• JCXH-211 injections with anti-PD-1 therapy for malignant solid tumors

  This study tests whether injecting JCXH-211 directly into tumors, together with an anti-PD-1 medicine, is safe and tolerable in adults with malignant solid tumors.

  Recruiting Phase 1/2 Immorna Biotherapeutics, Inc. · Guangzhou, Guangdong · NCT06781125

• Evaluating SHR-1681 for patients with advanced solid tumors

  This study is testing a new injection called SHR-1681 to see if it can safely help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shanghai, Shanghai Municipality · NCT06737731

• Investigating serum ferritin as a biomarker for immune-related adverse events

  This study is testing if a blood marker called serum ferritin can help doctors identify and predict immune-related side effects in patients with cancer receiving different types of treatment.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT06702566

• Using asciminib for treating chronic myeloid leukemia after prior therapy

  This study is testing if a new drug called asciminib can help people with chronic myeloid leukemia who have already tried one other treatment to see if it improves their condition.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06629584

• Evaluating JCXH-212 alone and with Toripalimab for treating malignant solid tumors

  This study is testing a new treatment called JCXH-212, both alone and with another drug called Toripalimab, to see if it can help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting Early Phase 1 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT05579275

• Biobank for patients with aggressive tumors

  This study is collecting blood and tumor samples from patients with aggressive cancers to see if they can find clues to create better, personalized treatments.

  Recruiting N.N. Petrov National Medical Research Center of Oncology · Saint Petersburg · NCT05539677

• Understanding rare solid tumors and their genetic factors

  This study is looking to learn more about rare solid tumors and their genetic factors by collecting samples and medical histories from people who have these tumors to help improve future treatments and prevention.

  Recruiting at 3 sites National Institutes of Health Clinical Center (CC) · Bethesda, Maryland and 2 other locations · NCT03739827

• Testing a new MRI method for solid tumors

  This study is testing a new MRI method using hyperpolarized pyruvate to see if it can give consistent results about the metabolism of different solid tumors in patients.

  Recruiting at 2 sites Memorial Sloan Kettering Cancer Center · Montvale, New Jersey and 1 other locations · NCT02421380

Related topics

Quick answers

How many Malignant Solid Tumors clinical trials are recruiting right now?

13, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 3 countries. The most sites are in China (8 trials), United States (4 trials), Russia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 4, Phase 2: 3, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →